Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLloyds Regulatory News (LLOY)

Share Price Information for Lloyds (LLOY)

Share Price is delayed by 15 minutes
Get Live Data
98.90    -1.20 (-1.20%)
Bid:
99.22
Ask:
99.28
Spread: 0.06 (0.06%)
Market Cap: £57.64b
LLOY Live PriceLast checked at - London Stock Exchange

Intraday Lloyds Share Chart

Publication of a Prospectus

7 Aug 2025 16:05

RNS Number : 4795U
Lloyds Bank PLC
07 August 2025
 

NOTICE

 

Publication of Prospectus

 

 

LLOYDS BANK PLC

(the Issuer)

 

€60 billion Global Covered Bond Programme, unconditionally and irrevocably guaranteed as to payments of interest and principal by Lloyds Bank Covered Bonds LLP

(the Programme)

 

The following Prospectus has been approved by the Financial Conduct Authority and is available for viewing:

 

Prospectus dated 7 August 2025 (the Prospectus) relating to the 60,000,000,000 Global Covered Bond Programme of Lloyds Bank plc, unconditionally and irrevocably guaranteed as to payments of interest and principal by Lloyds Bank Covered Bonds LLP.

 

To view the full Prospectus, please paste the relevant URL into the address bar of your browser.

 

http://www.rns-pdf.londonstockexchange.com/rns/4795U_1-2025-8-7.pdf

 

The Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at National Storage Mechanism | FCA.

For further information:

 

Investor Relations

Douglas Radcliffe

Group Investor Relations Director

Email: douglas.radcliffe@lloydsbanking.com

 

 

+44 (0) 20 7356 1571

 

Group Corporate Affairs

Matt Smith

Head of Media Relations

Email: matt.smith@lloydsbanking.com

 

 

+44 (0) 7788 352 487

Group Corporate Treasury

Kristofer Middleton

Head of Term Issuance and Capital Structuring

Email: Kristofer.Middleton@lloydsbanking.com

 

+44 (0) 20 7356 1122

 

Lloyds Bank plc

Registered Office

25 Gresham Street

London EC2V 7HN

 

Disclaimer - Intended Addressees

Please note that the information contained in this announcement and the Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom this announcement and the Prospectus are not addressed. Prior to relying on the information contained in this announcement and the Prospectus, you must ascertain from the Prospectus whether or not you are one of the intended addressees of the information contained in this announcement and the Prospectus.

 

In particular, this announcement and the Prospectus do not constitute an offer or invitation to subscribe for, or purchase, securities in the United States or in any other jurisdiction where such an offer or invitation would be unlawful. This announcement and the Prospectus are not for distribution in the United States or to U.S. persons (as defined below) other than to qualified institutional buyers within the meaning of and in reliance on Rule 144A of the U.S. Securities Act of 1933, as amended (the Securities Act). The securities described herein have not been, and will not be, registered under the Securities Act or under any relevant securities laws of any state of the United States of America and are subject to U.S. tax law requirements. The securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America (as such terms are defined in Regulation S under the Securities Act) except pursuant to registration or an exemption from the registration requirements of the Securities Act. There will be no public offering of the securities in the United States. For a description of the restrictions on offers and sales of the securities described herein, please refer to the Prospectus.

 

Your right to access this service is conditional upon complying with the above requirement.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PDIPKOBKPBKDDFK
Date   Source Headline
10th Dec 20254:39 pmRNSDirector/PDMR Shareholding
9th Dec 20254:00 pmRNSDirector/PDMR Shareholding
9th Dec 20257:03 amRNSCompletion of £1.7 billion Share Buyback Programme
8th Dec 20255:42 pmRNSTransaction in Own Shares
5th Dec 20255:50 pmRNSTransaction in Own Shares
4th Dec 20255:38 pmRNSTransaction in Own Shares
3rd Dec 20255:44 pmRNSTransaction in Own Shares
2nd Dec 20255:35 pmRNSTransaction in Own Shares
2nd Dec 20257:39 amRNSBoE Stress Test Passed
1st Dec 20255:31 pmRNSTransaction in Own Shares
28th Nov 20254:12 pmRNSTotal Voting Rights
27th Nov 20255:34 pmRNSTransaction in Own Shares
26th Nov 20255:38 pmRNSTransaction in Own Shares
25th Nov 20255:20 pmRNSTransaction in Own Shares
24th Nov 20255:41 pmRNSTransaction in Own Shares
21st Nov 20255:43 pmRNSTransaction in Own Shares
21st Nov 20253:00 pmRNSDirector/PDMR Shareholding
20th Nov 20255:28 pmRNSTransaction in Own Shares
20th Nov 20253:00 pmRNSBlock Listing of Shares
19th Nov 20255:38 pmRNSTransaction in Own Shares
19th Nov 20251:20 pmRNSDirector Declaration
19th Nov 20257:00 amRNSCurve Acquisition
18th Nov 20255:35 pmRNSTransaction in Own Shares
17th Nov 20255:40 pmRNSTransaction in Own Shares
14th Nov 20255:53 pmRNSTransaction in Own Shares
13th Nov 20255:27 pmRNSTransaction in Own Shares
12th Nov 20255:32 pmRNSTransaction in Own Shares
11th Nov 20255:33 pmRNSTransaction in Own Shares
11th Nov 20253:40 pmRNSDirector/PDMR Shareholding
10th Nov 20255:35 pmRNSTransaction in Own Shares
7th Nov 20255:42 pmRNSTransaction in Own Shares
6th Nov 20255:39 pmRNSTransaction in Own Shares
6th Nov 20252:33 pmRNSPublication of Final Terms
6th Nov 202510:32 amRNSDirector/PDMR Shareholding
5th Nov 20255:34 pmRNSTransaction in Own Shares
4th Nov 20255:42 pmRNSTransaction in Own Shares
3rd Nov 20255:45 pmRNSTransaction in Own Shares
31st Oct 20255:47 pmRNSTransaction in Own Shares
31st Oct 20254:38 pmRNSTotal Voting Rights
30th Oct 20255:16 pmRNSTransaction in Own Shares
29th Oct 20255:40 pmRNSTransaction in Own Shares
29th Oct 202510:31 amRNSNotification of Redemption
28th Oct 20255:29 pmRNSTransaction in Own Shares
27th Oct 20255:29 pmRNSTransaction in Own Shares
24th Oct 20255:56 pmRNSTransaction in Own Shares
24th Oct 202511:33 amRNSPublication of Suppl.Prospcts
24th Oct 20259:30 amRNSPublication of Suppl.Prospcts
23rd Oct 20255:49 pmRNSTransaction in Own Shares
23rd Oct 202512:25 pmRNSPublication of Suppl.Prospcts
23rd Oct 202511:58 amRNS2025 Q3 Interim Management Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.